Učitavanje...
Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells
The anti-CD20 monoclonal antibody, rituximab, provides a significant therapeutic benefit for patients with B-cell disorders. However, response to therapy varies and relapses are common, so an understanding of both inherited and acquired rituximab resistance is needed. In order to identify mechanisms...
Spremljeno u:
| Glavni autori: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
PeerJ Inc.
2013
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3628892/ https://ncbi.nlm.nih.gov/pubmed/23638367 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7717/peerj.31 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|